| Literature DB >> 21921991 |
Changkai Jia1, Wei Zhu, Shengwei Ren, Haijie Xi, Siyuan Li, Yiqiang Wang.
Abstract
PURPOSE: Suture placement and alkali burn to the cornea are often used to induce inflammatory corneal neovascularization (CorNV) models in animals. This study compares the changes in genome-wide gene expression under these two CorNV conditions in mice.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21921991 PMCID: PMC3171500
Source DB: PubMed Journal: Mol Vis ISSN: 1090-0535 Impact factor: 2.367
Figure 1Gross and histology presentations of corneas of corneal neovascularization models. A: Front views and side views of corneas with corneal neovascularization under slit lamp. B: Hematoxylin-eosin staining of corneas at limbus area and junction area, the latter of which refers to the area of the suture stitch in the S-corneal neovascularization model and the margin of direct chemical burn. The red scale bar represent 50 μm. Please note the difference of manifestations in these two models, especially in terms of transparency of the corneas.
Grouping of probes expressed in at least one corneal neovascularization model.
| Up-Reg | G1: 286 | G4: 99 | 0 | G9: 87 |
| Unchanged | G2: 203 | 0 | G6: 186 | 0 |
| Down-Reg | 0 | G5: 114 | G7: 244 | G10: 31 |
| Absent | G3: 97 | 0 | G8: 39 | 0 |
In each individual microarray, probes were identified as E (expressed), M (marginal), or A (absent) in an individual array after linearization and normalization as described in text, and only those classified as E were calculated for ratio values of the signal intensities of experimental samples against controls in the same arrays. For statistical purposes, probes marked as E in only one of three microarrays in one model were classified as A in this table. Down-Reg meant a signal intensity ratio of the experimental sample/control ≤0.5 plus FDR<1%, and Up-Reg meant ≥2.0 plus FDR<1%. Unchanged was for those of 0.5
Figure 2Hierarchical clustering of all 1,386 differentially expressed probes in either the S- or the CB-corneal neovascularization model. The color bar located in upper left corner stands for the folds of probe changes (in log2 value), while the gray color in the heat maps indicates that the value was absent in a specified microarray. S, suture; CB, chemical burn.
Figure 3Change of expression of PEDF and VEGF detected by western blot in corneal neovascularization. Samples were harvested at day 5 after S-CorNV induction and proteins of equivalent to one fifth cornea were loaded and detected by western blot. Please note that due to differential levels of two factors in samples, the exposing time of blotted membrane against X-films varied, namely about 45 s for PEDF, 2 min for GAPDH, and about 1 h for VEGF. Shown was one representative of three experiments that gave similar conclusions.
Enriched gene ontology terms according to biologic process in various groups of genes.
| chemotaxis (see | 18 |
| leukocyte chemotaxis | 9 |
| leukocyte migration | 10 |
| locomotory behavior | 18 |
| cell migration | 12 |
| immune response (see | 32 |
| defense response | 29 |
| inflammatory response (see | 21 |
| response to wounding | 25 |
| acute inflammatory response | 10 |
| acute-phase response | 6 |
| response to organic substance | 16 |
| response to molecule of bacterial origin | 5 |
| antigen processing and presentation of exogenous antigen | 6 |
| immunoglobulin mediated immune response | 7 |
| B cell mediated immunity | 7 |
| lymphocyte mediated immunity | 7 |
| positive regulation of response to stimulus | 10 |
| regulation of cytokine production (see | 8 |
| regulation of tumor necrosis factor production | 4 |
| response to oxidative stress | 6 |
| response to cytokine stimulus | 4 |
| positive regulation of acute inflammatory response | 3 |
| positive regulation of multicellular organismal process | 8 |
| cytokine-mediated signaling pathway | 5 |
| defense response to Gram-negative bacterium | 3 |
| eye development | 10 |
| lens development in camera-type eye | 5 |
| multicellular organismal homeostasis | 6 |
| extracellular structure organization | 8 |
| regulation of biomineral formation | 4 |
| regulation of bone mineralization | 4 |
| regulation of homeostatic process | 6 |
| cellular cation homeostasis | 8 |
| collagen fibril organization | 4 |
| homeostatic process | 17 |
| cellular homeostasis | 12 |
| vasculature development | 10 |
| epidermis development | 7 |
| sensory organ development | 10 |
| ectoderm development | 7 |
| epithelium development | 10 |
| epithelial cell differentiation | 7 |
| lens fiber cell differentiation | 3 |
| cellular iron ion homeostasis | 4 |
| positive regulation of developmental process | 9 |
| blood vessel development (refer to | 10 |
| intermediate filament-based process | 4 |
| icosanoid biosynthetic process | 4 |
| unsaturated fatty acid biosynthetic process | 4 |
| icosanoid metabolic process | 4 |
| mitosis | 8 |
| nuclear division | 8 |
| organelle fission | 8 |
| M phase | 9 |
| cell cycle phase | 9 |
| not any | |
| chordate embryonic development | 9 |
| embryonic development ending in birth or egg hatching | 9 |
| endothelial cell morphogenesis | 2 |
| not any | |
| lipid biosynthetic process | 15 |
| steroid metabolic process | 12 |
| steroid biosynthetic process | 8 |
| cholesterol metabolic process | 7 |
| carboxylic acid biosynthetic process | 8 |
| organic acid biosynthetic process | 8 |
| fatty acid biosynthetic process | 6 |
| oxidation reduction | 16 |
| cellular response to extracellular stimulus | 5 |
| cellular response to starvation | 4 |
| epithelium development | 9 |
| epithelial cell differentiation | 6 |
| epidermis development | 6 |
| keratinocyte differentiation | 4 |
| epidermal cell differentiation | 4 |
| Wnt receptor signaling pathway | 6 |
| ectoderm development | 6 |
| regulation of neuron differentiation | 5 |
| oxidation reduction (see | 19 |
| programmed cell death | 14 |
| retinol metabolic process | 3 |
| not any | |
| response to organic substance | 10 |
| response to steroid hormone stimulus | 4 |
| immune response | 8 |
| oxidation reduction | 9 |
| icosanoid metabolic process | 3 |
| not any | |
“Enrichment” means that a specific GO terms gives an Expression Analysis Systematic Explore (EASE) score less than 0.01. To simplify the presentation of the enriched terms, the GO terms that obviously duplicate others were not shown. For example, “cellular response to nutrient levels” in Group 6 was not shown due to its duplication to “cellular response to starvation.” Similarly, “Cell death,” “death,” and “apoptosis” in Group 7 were duplicates of “programmed cell death,” thus not shown either. aNumbers of probes in the specific group or GO term.
Genes associated with the gene ontology term “chemotaxis” in the upregulated gene list.
| NM_010185 | Fc receptor, IgE, high affinity I, gamma polypeptide | 10.03 | 8.98 | |
| NM_010188 | Fc receptor, IgG, low affinity III | 8.28 | 6.51 | |
| NM_013650 | S100 calcium binding protein A8 (calgranulin A) | 11.50 | 9.08 | |
| NM_009114 | S100 calcium binding protein A9 (calgranulin B) | 45.35 | 15.97 | |
| NM_011333 | chemokine (C-C motif) ligand 2 | 48.21 | 10.59 | |
| NM_011124 | chemokine (C-C motif) ligand 21A; predicted gene 1987 | 4.97 | 5.78 | |
| NM_009139 | chemokine (C-C motif) ligand 6 | 16.26 | 13.82 | |
| NM_021443 | chemokine (C-C motif) ligand 8 | 12.86 | 7.47 | |
| NM_011338 | chemokine (C-C motif) ligand 9 | 13.72 | 10.02 | |
| NM_009140 | chemokine (C-X-C motif) ligand 2 | 35.49 | 9.30 | |
| NM_203320 | chemokine (C-X-C motif) ligand 3 | 8.58 | 18.49 | |
| NM_009898 | coronin, actin binding protein 1A | 17.93 | 6.91 | |
| NM_008039 | formyl peptide receptor 2 | 23.07 | 15.79 | |
| NM_008361 | interleukin 1 beta | 22.61 | 9.88 | |
| NM_008489 | lipopolysaccharide binding protein | 5.32 | 4.26 | |
| NM_019932 | platelet factor 4 | 6.36 | 15.72 | |
| NM_011335 | chemokine (C-C motif) ligand 21B | 3.80 | 4.56 | |
| NM_023052 | chemokine (C-C motif) ligand 21C (leucine) | | | |
| NM_009141 | similar to LPS-induced CXC chemokine; chemokine (C-X-C motif) ligand 5 | 71.97 | 153.33 |
The values were the geometric mean of the ratios of signal intensity of experimental sample to normal control corneas.
Genes associated with the gene ontology term “immune response” in the upregulated gene list.
| NM_010819 | C-type lectin domain family 4, member d | 27.78 | 17.05 | |
| NM_020001 | C-type lectin domain family 4, member n | 14.52 | 15.83 | |
| NM_009841 | CD14 antigen | 25.69 | 20.90 | |
| NM_001042605 | CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated) | 2.44 | 3.04 | |
| NM_010185 | Fc receptor, IgE, high affinity I, gamma polypeptide | 10.03 | 8.98 | |
| NM_010188 | Fc receptor, IgG, low affinity III | 8.28 | 6.51 | |
| NM_007388 | acid phosphatase 5, tartrate resistant | 2.60 | 4.30 | |
| NM_011333 | chemokine (C-C motif) ligand 2 | 48.21 | 10.59 | |
| NM_011124 | chemokine (C-C motif) ligand 21A; predicted gene 1987 | 4.97 | 5.78 | |
| NM_009139 | chemokine (C-C motif) ligand 6 | 16.26 | 13.82 | |
| NM_021443 | chemokine (C-C motif) ligand 8 | 12.86 | 7.47 | |
| NM_011338 | chemokine (C-C motif) ligand 9 | 13.72 | 10.02 | |
| FNM_009915 | chemokine (C-C motif) receptor 2 | 27.51 | 16.93 | |
| NM_008176 | chemokine (C-X-C motif) ligand 1 | 14.52 | 7.16 | |
| NM_019568 | chemokine (C-X-C motif) ligand 14 | 3.34 | 2.30 | |
| NM_009140 | chemokine (C-X-C motif) ligand 2 | 35.49 | 9.30 | |
| NM_203320 | chemokine (C-X-C motif) ligand 3 | 8.58 | 18.49 | |
| NM_007574 | complement component 1, q subcomponent, C chain | 4.22 | 3.86 | |
| NM_007572 | complement component 1, q subcomponent, alpha polypeptide | 5.50 | 7.72 | |
| NM_009777 | complement component 1, q subcomponent, beta polypeptide | 5.22 | 5.85 | |
| NM_008147 | leukocyte immunoglobulin-like receptor, subfamily B, member 4 | 36.73 | 24.18 | |
| NM_010378 | histocompatibility 2, class II antigen A, alpha; | 2.53 | 3.32 | |
| NM_010381 | histocompatibility 2, class II antigen E alpha | 3.50 | 4.17 | |
| NM_207105 | histocompatibility 2, class II antigen A, beta 1 | 4.38 | 4.84 | |
| NM_010382 | histocompatibility 2, class II antigen E beta | 3.56 | 4.51 | |
| NM_008361 | interleukin 1 beta | 22.61 | 9.88 | |
| NM_153511 | interleukin 1 family, member 9 | 2.20 | 2.83 | |
| NM_008489 | lipopolysaccharide binding protein | 5.32 | 4.26 | |
| NM_019932 | platelet factor 4 | 6.36 | 15.72 | |
| NM_011335 | similar to beta chemokine Exodus-2; chemokine (C-C motif) ligand 21B; | 3.80 | 4.56 | |
| NM_009760 | predicted gene 14506; BCL2/adenovirus E1B interacting protein 3 | 3.76 | 3.11 | |
| NM_023785 | pro-platelet basic protein | 61.39 | 32.60 | |
| NM_009141 | similar to LPS-induced CXC chemokine; chemokine (C-X-C motif) ligand 5 | 71.97 | 153.33 |
Genes associated with the gene ontology term “inflammatory response” in the upregulated gene list.
| NM_010169 | coagulation factor II (thrombin) receptor | 2.97 | 3.30 | |
| NM_009252 | serine (or cysteine) peptidase inhibitor, clade A, member 3N | 17.13 | 10.07 | |
| NM_009117 | serum amyloid A 1 | 26.09 | 9.43 | |
| NM_011315 | serum amyloid A 3 | 85.23 | 35.01 | |
| NM_133977 | transferrin | 3.41 | 2.73 |
Among all 21 genes in the GO terms of “inflammatory response,” the ones that overlapped with those in “immune response” were not shown, they included Cd14, Fcgr3, Ccl2, Ccl21a, Ccl8, Ccr2, Cxcl1, Cxcl2, Cxcl3, C1qg, C1qa, C1qb, Il1b, Lbp, Ccl21b/Ccl21c, and Cxcl5.
Genes associated with the gene ontology term “regulation of cytokine production” in the upregulated gene list.
| NM_010169 | coagulation factor II (thrombin) receptor | 2.97 | 3.30 | |
| NM_010442 | heme oxygenase (decycling) 1 | 6.21 | 4.82 | |
| NM_011157 | serglycin | 6.87 | 7.29 |
Among all 8 genes in the GO term of “regulation of cytokine production,” the ones that overlapped with those in “immune response” were not shown, they included Cd14, Fcer1g, Fcgr3, Il1b, and Lbp.
Genes associated with the gene ontology term “blood vessel development” that changed in either corneal neovascularization model.
| NM_198725 | EGF-like domain 7 | 4.26 | 3.08 | |
| NM_010228 | FMS-like tyrosine kinase 1 | 2.01 | 2.31 | |
| NM_009930 | collagen, type III, alpha 1 | 12.87 | 16.57 | |
| NM_015734 | collagen, type V, alpha 1 | 2.99 | 3.12 | |
| NM_010442 | heme oxygenase (decycling) 1 | 6.21 | 4.82 | |
| NM_008361 | interleukin 1 beta | 22.61 | 9.88 | |
| NM_008610 | matrix metallopeptidase 2 | 4.32 | 4.34 | |
| NM_007707 | suppressor of cytokine signaling 3 | 3.58 | 2.17 | |
| NM_009382 | thymus cell antigen 1, theta | 3.57 | 2.68 | |
| NM_013749 | tumor necrosis factor receptor superfamily, member 12a | 4.08 | 4.81 | |
| NM_007709 | Cbp/p300-interacting transactivator with Glu/Asp-rich C-terminal domain 1 | 2.54 | 1.00 | |
| NM_053087 | epithelial mitogen | 2.72 | 1.88 | |
| NM_009929 | collagen, type XVIII, alpha 1 | 1.96 | 2.10 | |
| NM_030250 | nuclear undecaprenyl pyrophosphate synthase 1 homolog (S. cerevisiae) | 1.97 | 2.04 | |
| NM_194054 | reticulon 4 | 1.72 | 2.48 | |
| NM_007742 | collagen, type I, alpha 1 | 3.93 | ||
| NM_007950 | epiregulin | 2.40 | ||
| NM_009769 | Kruppel-like factor 5 | 0.36 | 1.40 | |
| NM_008943 | presenilin 1 | 0.42 | 0.67 | |
| NM_009154 | semaphorin, 5A | 0.42 | 0.45 | |
| NM_016907 | serine protease inhibitor, Kunitz type 1 | 0.49 | 0.84 | |
| NM_009373 | transglutaminase 2, C polypeptide | 0.27 | 0.21 | |
| NM_010197 | fibroblast growth factor 1 | 0.66 | 0.29 | |
| NM_023517 | tumor necrosis factor (ligand) superfamily, member 13 | 0.70 | 0.49 | |
| NM_026924 | ovo-like 2 (Drosophila) | 0.43 |
Genes associated with the gene ontology term “structural constituent of eye lens” according to “molecular function” in upregulated genes.
| NM_013501 | crystallin, alpha A | 18.90 | 6.31 | |
| NM_009965 | crystallin, beta A1 | 9.07 | 4.79 | |
| NM_021541 | crystallin, beta A2 | 17.96 | 4.06 | |
| NM_023695 | crystallin, beta B1 | 20.01 | 4.76 | |
| NM_007773 | crystallin, beta B2 | 16.68 | 6.51 | |
| NM_021352 | crystallin, beta B3 | 10.81 | 3.04 | |
| NM_144761 | crystallin, gamma B | 12.38 | 4.36 | |
| NM_007775 | crystallin, gamma C | 39.09 | 4.02 | |
| NM_007776 | crystallin, gamma D | 16.12 | 4.61 | |
| NM_007777 | crystallin, gamma E | 14.08 | 3.70 | |
| NM_027010 | crystallin, gamma F | 14.93 | 4.78 | |
| NM_009967 | crystallin, gamma S | 29.49 | 6.45 |
Gene list assocated with the gene ontology term “oxidation reduction” in downregulated genes.
| NM_028133 | EGL nine homolog 3 (C. elegans) | 0.47 | 0.36 | |
| NM_008706 | NAD(P)H dehydrogenase, quinone 1 | 0.26 | 0.33 | |
| NM_007409 | alcohol dehydrogenase 1 (class I) | 0.12 | 0.17 | |
| NM_009626 | alcohol dehydrogenase 7 (class IV) | 0.11 | 0.40 | |
| XM_974140 | alcohol dehydrogenase 3, member b2 | 0.34 | 0.38 | |
| NM_013467 | aldehyde dehydrogenase family 1, subfamily A1 | 0.35 | 0.25 | |
| NM_007436 | aldehyde dehydrogenase family 3, subfamily A1 | 0.24 | 0.13 | |
| NM_013777 | aldo-keto reductase family 1, member C12 | 0.32 | 0.16 | |
| NM_013778 | aldo-keto reductase family 1, member C13 | 0.32 | 0.16 | |
| NM_023066 | aspartate-beta-hydroxylase | 0.23 | 0.26 | |
| NM_007819 | cytochrome P450, family 3, subfamily a, polypeptide 13 | 0.44 | 0.29 | |
| NM_018887 | cytochrome P450, family 39, subfamily a, polypeptide 1 | 0.19 | 0.31 | |
| NM_172306 | cytochrome P450, family 4, subfamily a, polypeptide 12B | 0.11 | 0.39 | |
| NM_177406 | cytochrome P450, family 4, subfamily a, polypeptide 12a | 0.23 | 0.49 | |
| NM_025968 | prostaglandin reductase 1 | 0.25 | 0.14 | |
| NM_028725 | short chain dehydrogenase/reductase family 42E, member 1 | 0.30 | 0.21 | |
| NM_201640 | cytochrome P450, family 4, subfamily a, polypeptide 10 | 0.14 | 0.41 | |
| NM_007453 | similar to Peroxiredoxin-6 | 0.30 | 0.38 | |
| NM_028454 | transmembrane 7 superfamily member 2 | 0.34 | 0.41 |
Genes of specific interest.
| NM_026358 | Corneal endothelial-specific protein 1 | 0.25±0.04 | 0.07±0.00 | |
| NM_009930 | collagen, type III, alpha 1 | 12.94±1.69 | 16.90±4.05 | |
| NM_007735 | collagen, type IV, alpha 4 | 0.31±0.07 | 0.22±0.08 | |
| NM_007737 | collagen, type V, alpha 2 | 5.16±3.19 | 3.08±0.37 | |
| NM_194069 | interferon, alpha-inducible protein 27 like 1 | 0.41±0.04 | 0.39±0.08 | |
| NM_027320 | interferon-induced protein 35 | 0.40±0.07 | 0.49±0.13 | |
| NM_133871 | interferon-induced protein 44 | 0.43±0.04 | 0.42±0.07 | |
| NM_008331 | interferon-induced protein with tetratricopeptide repeats 1 | 0.44±0.07 | 0.37±0.09 | |
| NM_025378 | interferon induced transmembrane protein 3 | 2.80±0.14 | 4.52±0.04 | |
| NM_008438 | keratocan | 0.24±0.06 | 0.20±0.03 | |
| NM_010662 | keratin 13 | 3.25±0.44 | 3.23±1.58 | |
| NM_016958 | keratin 14 | 5.80±2.16 | 5.08±2.95 | |
| NM_008470 | keratin 16 | 14.16±3.28 | 6.09±0.69 | |
| NM_010663 | keratin 17 | 10.41±1.26 | 8.08±1.42 | |
| NM_008471 | keratin 19 | 2.71±0.70 | 3.92±0.33 | |
| NM_010661 | keratin 12 | 0.26±0.09 | 0.08±0.03 | |
| NM_033373 | keratin 23 | 2.02±0.51 | 2.12±0.28 | |
| NM_008475 | keratin 4 | 4.76±0.73 | 4.49±0.17 | |
| NM_033073 | keratin 7 | 4.49±1.41 | 6.02±0.82 | |
| XM_138237 | serine (or cysteine) peptidase inhibitor, clade A, member 3F | 9.87±3.06 | 7.78±0.52 | |
| NM_009252 | serine (or cysteine) peptidase inhibitor, clade A, member 3N | 17.36±3.33 | 10.30±2.67 | |
| NM_009126 | serine (or cysteine) peptidase inhibitor, clade B, member 3A | 18.78±14.65 | 17.32±3.41 | |
| NM_201363 | serine (or cysteine) peptidase inhibitor, clade B, member 3C | 20.51±11.56 | 27.78±5.39 | |
| NM_201376 | serine (or cysteine) peptidase inhibitor, clade B, member 3D | 24.03±18.60 | 38.29±12.10 | |
| NM_011454 | serine (or cysteine) peptidase inhibitor, clade B, member 6b | 5.28±1.79 | 7.55±0.79 | |
| NM_009255 | serine (or cysteine) peptidase inhibitor, clade E, member 2 | 3.16±0.24 | 4.28±0.36 | |
| NM_009825 | serine (or cysteine) peptidase inhibitor, clade H, member 1 | 2.09±0.43 | 3.25±0.63 | |
| XM_135671 | Predicted | PHD finger protein 11 | 0.46±0.12 | 0.46±0.10 |
| NM_183249 | Predicted | RIKEN cDNA 1100001G20 gene | 6.73±2.53 | 6.55±0.85 |
| XM_128979 | Predicted | RIKEN cDNA C330008K14 gene | 5.99±1.76 | 4.15±0.81 |
| NM_175417 | Predicted | RIKEN cDNA 9530008L14 gene | 0.30±0.04 | 0.10±0.01 |
| NM_173421 | Predicted | cDNA sequence BC030476 | 0.34±0.06 | 0.27±0.03 |
| NM_029733 | Predicted | RIKEN cDNA 2010005H15 gene | 3.72±0.56 | 2.21±0.40 |
| NM_028166 | Predicted | RIKEN cDNA 1600014C10 gene | 0.31±0.05 | 0.38±0.04 |
| NM_027171 | Predicted | RIKEN cDNA 2310057J16 gene | 0.42±0.15 | 0.29±0.10 |
| XM_489536 | Predicted | RIKEN cDNA 6430590I03 gene | 0.33±0.03 | 0.34±0.07 |
| NM_134133 | Predicted | RIKEN cDNA 2010002N04 gene | 9.75±1.85 | 6.34±0.66 |
| NM_001001332 | Predicted | cDNA sequence BC1179090 | 6.73±0.98 | 2.99±0.35 |
| NM_026412 | Predicted | DNA segment, Chr 2, ERATO Doi 750 | 2.76±0.67 | 2.21±1.00 |
| XM_486478 | Predicted | ferritin light-chain 1 | 2.15±0.34 | 2.07±0.12 |
| NM_001082547 | Predicted | Gm 5483 | 11.52±1.39 | 4.95±0.51 |